EU Ruling Turns Days Into €millions For Companies
This article was originally published in Scrip
Executive Summary
Just a few days could make a big difference for your company, perhaps millions of Euros. Thanks to a ruling from the Court of Justice of the European Union, some innovative products could have their market exclusivity period extended in some EU markets by a number of days or maybe weeks. This may not seem much on the surface, but it could mean a windfall for the originator company and isn't all bad news for the generics companies, explains Mike Gilbert, a partner at Marks & Clerk Solicitors.
You may also be interested in...
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: